Response Genetics Inc.

Kathy Danenberg has been the Chief Executive Officer for Response Genetics, Inc. since 2002. With her vision and leadership the Company has become a leading provider of molecular analysis services for some of the world s leading pharmaceutical companies. Ms. Danenberg s began her career in molecular research and developed broad expertise in a variety of areas and applications. While at USC, Ms. Danenberg invented a breakthrough patented method to extract RNA from formalin-fixed paraffin embedded tissue specimens which became the basis for the establishment of Response Genetics, Inc. , Ms. Danenberg's research on the kinetic mechanism of thymidylate synthase provided the rationale for use of the 5-FU-leucovorin combination in colorectal cancer. She designed and carried out experiments demonstrating that 5-FU could alter RNA splicing and developed methods for using the polymerase chain reaction to quantitatively measure gene expression levels in tumor tissues. Prior to her work at USC, Ms. Danenberg worked with the renowned enzyme kineticist Dr. W.W. Cleland at the University of Wisconsin to elucidate the mechanism of action of the enzyme hexokinase. Ms Danenberg has a world-wide reputation in the field of pharmaco genomics and is a frequent lecturer on a variety of subjects in this field. Ms. Danenberg has published over 70 peer-reviewed articles and is an invited lecturer for various scientific meetings both nationally and internationally in the field of pharmacogenomics. She received a B.S. in Biochemistry from the University of Wisconsin.

Thomas Stankovich joined us as our Vice President, Chief Financial Officer and Secretary in December 2006. Mr. Stankovich has gained financial and business experience over the past 20 years working in both domestic and international operations with publicly-traded companies in the pharmaceutical and biotechnology industries. Mr. Stankovich most recently was Executive Vice President and Chief Financial officer at Cobalis Corp. from December 2005 to December 2006. Prior to his position at Cobalis Corp., he worked at MP Biomedicals, LLC where he served as Senior Vice President and Chief Financial Officer from July 2003 to December 2005. He served as Senior Vice President and Chief Financial Officer for Ribapharm, Inc. from December 2001 to January 2003 (now part of Valeant Pharmaceuticals International) where he helped complete an initial public offering in April 2002. Since 1986, Mr. Stankovich has served in various executive financial management positions for ICN Pharmaceuticals, Inc. (now renamed Valeant Pharmaceuticals International) including Vice President, Chief Financial Officer for ICN International A.G., and Vice President and Controller for ICN Europe. Mr. Stankovich holds Bachelor of Science degrees in both accounting and finance from California State University, Northridge.

Denise McNairn joined Response Genetics as our Vice President and General Counsel in February 2007. Prior to joining the business, from 2001 to 2007, Ms. McNairn was an attorney at Kenyon & Kenyon LLP. Her legal experience covers all areas of intellectual property, including patent and trademark litigation, patent prosecution, and licensing. Ms. McNairn's patent litigation experience is focused in the life sciences, including pharmaceuticals, biotechnology and devices. Prior to Kenyon & Kenyon, Ms. McNairn worked as a Technology Transfer Specialist at the National Cancer Institute Technology Transfer Branch, where she began her career in drafting and negotiating transactional agreements. Prior to beginning her legal career, Ms. McNairn worked a number of years in the biotechnology field and was an infectious disease researcher. Ms. McNairn received her B.S. from Virginia Polytechnic Institute and State University, an M.S. from Johns Hopkins University and her J.D. from the University of Maryland School of Law.

Ms. Cooc has been the Director of Regulatory Affairs for Response Genetics since 2005. Ms. Cooc joined Response Genetics in 2001 and held positions in both research and operations, including as Head of Operations, North America. Prior to this she gained extensive experience in clinical diagnostics and clinical development equirements while holding various laboratory positions with publicly held companies, including Quest Diagnostics Inc. Prior to Quest Diagnostics, Ms. Cooc held research and clinical diagnostics positions at SmithKline Beechem Clinical Laboratory and Loyola Marymount University. Ms. Cooc received a Masters in Regulatory Science from the University of Southern California and a B.S. in Biochemistry from Loyola Marymount University.

David P. Kelsen, M.D. has served as a director of Response Genetics since March 2000. Dr. Kelsen has been a Professor of Medicine at Cornell University Medical College since 1992, an attending physician at Memorial Hospital for Cancer and Allied Diseases since 1991, and has held numerous hospital and administrative positions at Memorial Sloan-Kettering Cancer Center since 1980, including among others the current position of Chief, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine. Dr. Kelsen received his M.D. from Hahnemann Medical College and a B.A. from Temple University.

David R. Gandara, MD, is Professor of Medicine at the University of California, Davis School of Medicine and Associate Director of Clinical Research, and Director of Thoracic Oncology at the University of California, Davis Cancer Center. Dr. Gandara is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. Dr. Gandara is an active member of the Scientific Leadership Council in Lung Cancer. Dr. Gandara is chair of the Southwest Oncology Group (SWOG) Lung Committee, and co-chair of the NCI-directed Investigational Drug Steering Committee. He has written over 300 articles, book chapters, abstracts and editorials. He is editor-in-chief of Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals. He is President Elect for the International Association for the Study of Lung Cancer (IASLC) and serves on the board of directors. He also served as secretary-treasurer and a member of the board of directors for the American Society of Clinical Oncology (ASCO). Dr. Gandara is a requested speaker both nationally and internationally. His most recent presentations include Incorporation of Laboratory Correlative Science into Clinical Trial Design and Development of Predictive Biomarkers of Response to Novel Therapeutic Agents. After receiving his medical degree from the University of Texas Medical Branch in Galveston, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma and a fellow at the Letterman Army Medical Center Presidio of San Francisco.

Dr. David Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. In addition, he is Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has served as a Director of Imclone since January 2004. He is a founder of several private biotechnology companies and has served on the scientific advisory boards of many private and public companies including Medimmune, Telik, Roche and Amgen. He was formerly on the Board of Scientific Counselors at the NIDCR and is currently a member of the Recombinant DNA Advisory Committee at the National Institute of Health (NIH). Dr. Sidransky is a member of numerous editorial boards. He has over 250 peer-reviewed publications, has contributed more than 40 cancer reviews, and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research.

Dr. Lenz is an Associate Professor of Medicine in the USC Department of Medicine, the Scientific Director of the Cancer Genetics Unit and the Associate Director of the Gastrointestinal Oncology Program at the USC/Kenneth Norris Jr. Comprehensive Cancer Center. In 1995 Dr Lenz was selected for the prestigious ASCO Career Development Award. In 2000 he was awarded the highly competitive Midcareer Development Award from the National Cancer Institute. He is the Institutional Principal Investigator on numerous innovative clinical trials with novel and promising anticancer drugs. Dr Lenz earned his MD degree at the Johannes-Gutenberg Universitat in Mainz, Germany and had special fellowship training at George Washington University and Harvard Medical School..

Dr. Danenberg has been a Professor of Biochemistry and Molecular Biology at the University of Southern California School of Medicine (USC) since 1987. Dr. Danenberg received his B.S. degree in chemistry at Case-Western Reserve University and his M.S. in chemistry at USC. He obtained his Ph.D. from the University of California at Santa Barbara. Dr. Danenberg performed post-doctoral work at the McArdle Laboratory for Cancer Research at the University of Wisconsin under the world-famous Dr. Charles Heidelberger, the inventor of the still widely used drug 5-FU. While in Heidelberger s laboratory, Dr. Danenberg elucidated the biochemical mechanism by which 5-FU interacts with its major target in cells, the enzyme thymidylate synthase (TS). This discovery was fundamental in understanding how 5-FU works to inhibit tumor growth.